Résultats de la recherche - 63 results
Cervical morbidity in Alsace, France: results from a regional organized cervical cancer screening program.
whole female population were obtained from the two cancer registries. During 2008-2011, 565 153 smears were performed in 498 913 women aged 25-64 years, representing an average of 1.13 smears/woman and ...
Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.
0.97 to 1.02). However, hrHPV assays based on signal amplification were less sensitive on self samples (pooled ratio 0.85, 95% confidence interval 0.80 to 0.89). The specificity to exclude CIN2 + was 2% ...
Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials.
those associated with vaccine HPV types and any cervical precancer. Exposure groups were: women aged: 15-26 or 24-45 years being initially negative for high-risk HPV (hrHPV) or negative for the vaccine ...
Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
specificity of 1.00 (95% CI, 0.99 to 1.01) (value of >0.05 in all cases). Regardless of the clinical outcome (CIN2 + or CIN3 +), age restriction (women ≥30 years old), or comparator test used, Anyplex ...
Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
Publication Type: Peer reviewed scientific article Authors: Akbari, Ajmal; Vanden Broeck, Davy; Benoy, Ina; Padalko, Elizaveta; Bogers, Johannes; M. Arbyn Source: Virol J, Volume 15, Issue 1 (2018) ...
VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples
Publication Type: Peer reviewed scientific article Authors: M. Arbyn; E Peeters; I Benoy; D Vanden Broeck; J Bogers; P De Sutter; G Donders; W Tjalma; S Weyers; Cuschieri, K; Poljak, M; J Bonde; ...
Clinical Evaluation of INNO-LiPA HPV Genotyping II Assay Using the VALGENT Framework.
assessment, we considered it as high-risk (hr) HPV positive when at least one of the following HPV types was present: HPV16, HPV18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, and ...
The use of the permanent sample (eps) to study the returnto- work after cancer. Challenges and opportunities for research
multidisciplinary consultation (MOC) in 2011. RESULTS: By the end of follow-up, 24 % of the workers were deceased. Among those who survived 26 % are unable to work, 12 % are unemployed and 63 % do not receive any ...
Early effects of human papillomavirus vaccination in Belgium.
Publication Type: Peer reviewed scientific article Authors: Merckx, Mireille; Vanden Broeck, Davy; Benoy, Ina; Depuydt, Christophe; Weyers, Steven; M. Arbyn Source: Eur J Cancer Prev, Volume 24, ...
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
screening rounds at a 3-year interval (n = 746). The GP5 +/6+- PCR EIA (EIA) was used as a comparator assay and showed sensitivities of 94.1% and 98.2% for CIN2 + and CIN3 +, respectively, with a clinical ...